Business
TNI BioTech, Inc. Announces the Formation of its New Medical Advisory Board and Initial Member Appointments
TNI BioTech, Inc. Announces the Formation of its New Medical Advisory Board and Initial Member Appointments.
About this update from Biostax Corp.
[{"type":"text","content":" 0 0 1 1441 8214 Brinen & Associates, LLC 68 19 9636 14.0 0 Normal 0 false false false EN-US JA X-NONE TNI BioTech, Inc. Announces the Formation of its New Medical Advisory Board 
and Initial Board Member AppointmentsWest Palm Beach, Florida, July 16, 2012 – TNI BioTech, Inc. (pinksheets:TNIB) announced the formation of its new Medical Advisory Board. The first appointments to the Advisory Board consists of a number of multi-disciplinary and highly respected clinicians, practitioners and economists.These are the first of a number of appointments to the Advisory Board that will also advise on other critical issues, such as health economics and reimbursement to help TNI BioTech meet the changing needs of the global market.Dr. Eugene Youkilis, President of TNI BioTech adds: “With such a varied and experienced panel of experts, we are bound to create new and exciting opportunities to help forge us ahead and innovations specifically aimed at meeting clinician and patient needs around the world. I am delighted that the TNI BioTech Advisory Board has been formed and I look forward to working with the group as we seek to pioneer new ideas and techniques in the treatment of various immune system related diseases.”Members of the TNI BioTech Advisory Board are:Professor Angus Dalgleish MD, FRACP, FRCP, FRCPath, FMedSci Professor Angus Dalgleish studied medicine at University College London where he obtained an MBBS and a BSc in Anatomy. He is a Fellow of The Royal College of Physicians of the UK and Australia, Royal College of Pathologists and The Academy of Medical Scientists. He also trained in Internal Medicine and Oncology in Brisbane and Sydney. Following an interest in how viruses caused cancer, he undertook a PhD with Professor Robin Weiss, a FRS at the Institute of Cancer Research and Royal Marsden Hospital before becoming a senior clinical scientist at the MRC Clinical Research Center in Northwick Park. He was appointed to Foundation Chair of Oncology at St. George’s University of London in 1991. His main interest there has been the immunology of cancer and the development of immunotherapies to treat, in particular, melanoma. In 1997, he founded Onyvax Ltd., a privately funded biotechnology company developing cancer vaccines, and currently holds a position as Research Director.Professor...